171 related articles for article (PubMed ID: 37755725)
1. Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement.
Mastacouris N; Tannenbaum R; Strunk A; Koptyev J; Aarts P; Alhusayen R; Bechara FG; Benhadou F; Bettoli V; Brassard A; Brown D; Choon SE; Coutts P; da Silva DLF; Daveluy S; Dellavalle RP; Del Marmol V; Emtestam L; Gebauer K; George R; Giamarellos-Bourboulis EJ; Goldfarb N; Hamzavi I; Hazen PG; Horváth B; Hsiao J; Ingram JR; Jemec GBE; Kirby JS; Lowes MA; Marzano AV; Matusiak L; Naik HB; Okun MM; Oon HH; Orenstein LAV; Paek SY; Pascual JC; Fernandez-Peñas P; Resnik BI; Sayed CJ; Thorlacius L; van der Zee HH; van Straalen KR; Garg A
JAMA Dermatol; 2023 Nov; 159(11):1258-1266. PubMed ID: 37755725
[TBL] [Abstract][Full Text] [Related]
2. Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary.
Frew JW; Lowes MA; Goldfarb N; Butt M; Piguet V; O'Brien E; Ingram J; Jemec GBE; Tan J; Zouboulis C; Alavi A; Kirby JS
JAMA Dermatol; 2021 Apr; 157(4):449-455. PubMed ID: 33688910
[TBL] [Abstract][Full Text] [Related]
3. Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
Wainman HE; Chandran NS; Frew JW; Garg A; Gibbons A; Gierbolini A; Horvath B; Jemec GB; Kirby B; Kirby J; Lowes MA; Martorell A; McGrath BM; Naik HB; Oon HH; Prens E; Sayed CJ; Thorlacius L; Van der Zee HH; Villumsen B; Ingram JR
Br J Dermatol; 2024 Mar; 190(4):510-518. PubMed ID: 37976235
[TBL] [Abstract][Full Text] [Related]
4. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.
Thorlacius L; Ingram JR; Villumsen B; Esmann S; Kirby JS; Gottlieb AB; Merola JF; Dellavalle R; Nielsen SM; Christensen R; Garg A; Jemec GBE;
Br J Dermatol; 2018 Sep; 179(3):642-650. PubMed ID: 29654696
[TBL] [Abstract][Full Text] [Related]
5. Surgical Procedural Definitions for Hidradenitis Suppurativa Developed by Expert Delphi Consensus.
Bui H; Bechara FG; George R; Goldberg S; Hamzavi I; Kirby JS; Saylor D; Sayed CJ
JAMA Dermatol; 2023 Apr; 159(4):441-447. PubMed ID: 36811866
[TBL] [Abstract][Full Text] [Related]
6. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.
Thorlacius L; Garg A; Riis PT; Nielsen SM; Bettoli V; Ingram JR; Del Marmol V; Matusiak L; Pascual JC; Revuz J; Sartorius K; Tzellos T; van der Zee HH; Zouboulis CC; Saunte DM; Gottlieb AB; Christensen R; Jemec GBE
Br J Dermatol; 2019 Sep; 181(3):483-491. PubMed ID: 30724351
[TBL] [Abstract][Full Text] [Related]
7. Expert consensus on unmet needs, referral criteria and treatment goals for hidradenitis suppurativa in Saudi Arabia.
Eshmawi MT; Yousef Al-Mudaiheem H; Fatani M; Binamer Y; Alajlan M; Alharithy R; Alotaibi H; Almohanna HM; Alsantali A; Madani A; Al-Faraidy N; Bechara FG; Hamden Al-Jedaie A
J Dermatolog Treat; 2024 Dec; 35(1):2353693. PubMed ID: 38862417
[No Abstract] [Full Text] [Related]
8. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.
Thorlacius L; Garg A; Ingram JR; Villumsen B; Theut Riis P; Gottlieb AB; Merola JF; Dellavalle R; Ardon C; Baba R; Bechara FG; Cohen AD; Daham N; Davis M; Emtestam L; Fernández-Peñas P; Filippelli M; Gibbons A; Grant T; Guilbault S; Gulliver S; Harris C; Harvent C; Houston K; Kirby JS; Matusiak L; Mehdizadeh A; Mojica T; Okun M; Orgill D; Pallack L; Parks-Miller A; Prens EP; Randell S; Rogers C; Rosen CF; Choon SE; van der Zee HH; Christensen R; Jemec GBE
Br J Dermatol; 2018 Mar; 178(3):715-721. PubMed ID: 29080368
[TBL] [Abstract][Full Text] [Related]
9. Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes.
Thorlacius L; Ingram JR; Garg A; Villumsen B; Esmann S; Kirby JS; Gottlieb AB; Merola JF; Dellavalle R; Christensen R; Jemec GB
BMJ Open; 2017 Feb; 7(2):e014733. PubMed ID: 28219961
[TBL] [Abstract][Full Text] [Related]
10. Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation.
Kozera EK; Porter M; Paek SY; Mintoff D; McMeniman E; Oon HH; Chandran NS; Glasenhardt K; Ring HC; Frew JW
Dermatology; 2024; 240(3):494-506. PubMed ID: 37963431
[TBL] [Abstract][Full Text] [Related]
11. Expert consensus on priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa: a Delphi consensus study.
Yamanaka-Takaichi M; Revankar R; Shih T; Gall M; Hsiao JL; Shi VY; Alavi A
Arch Dermatol Res; 2023 Sep; 315(7):2129-2136. PubMed ID: 36951970
[TBL] [Abstract][Full Text] [Related]
12. Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document.
Alavi A; Lynde C; Alhusayen R; Bourcier M; Delorme I; George R; Gooderham M; Gulliver W; Kalia S; Marcoux D; Poulin Y
J Cutan Med Surg; 2017; 21(6):513-524. PubMed ID: 28639459
[TBL] [Abstract][Full Text] [Related]
13. Core Outcome Set for Actinic Keratosis Clinical Trials.
Reynolds KA; Schlessinger DI; Vasic J; Iyengar S; Qaseem Y; Behshad R; DeHoratius DM; Denes P; Drucker AM; Dzubow LM; Etzkorn JR; Harwood C; Kim JYS; Lee EH; Lissner GS; Marghoob AA; Matin RN; Mattox A; Mittal BB; Thomas JR; Zhou XA; Zloty D; Schmitt J; Kirkham J; Poon E; Sobanko JF; Cartee TV; Maher IA; Alam M
JAMA Dermatol; 2020 Mar; 156(3):326-333. PubMed ID: 31939999
[TBL] [Abstract][Full Text] [Related]
14. A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e-Delphi process and consensus meeting.
Langbroek GB; Wolkerstorfer A; Horbach SER; Spuls PI; Kelly KM; Robertson SJ; van Raath MI; Al-Niaimi F; Kono T; Boixeda P; Laubach HJ; Badawi AM; Rubin AT; Haedersdal M; Manuskiatti W; van der Horst CMAM; Ubbink DT;
Br J Dermatol; 2022 Nov; 187(5):730-742. PubMed ID: 35762296
[TBL] [Abstract][Full Text] [Related]
15. Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts.
Rick JW; De DR; Shih T; Alavi A; Kirby JS; Naik HB; Frew JW; Sayed CJ; Hsiao JL; Shi VY
Skin Appendage Disord; 2022 Jul; 8(4):287-290. PubMed ID: 35979524
[TBL] [Abstract][Full Text] [Related]
16. New treatments and new assessment instruments for Hidradenitis suppurativa.
van Straalen KR; Ingram JR; Augustin M; Zouboulis CC
Exp Dermatol; 2022 Sep; 31 Suppl 1(Suppl 1):33-39. PubMed ID: 35582833
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
Garg A; Zema C; Ciaravino V; Rolleri R; Peterson L; Garcia L; Massaro T; Jemec GBE; Kirby JS; Thorlacius L; Ingram JR
JAMA Dermatol; 2023 Jun; 159(6):606-612. PubMed ID: 37099284
[TBL] [Abstract][Full Text] [Related]
18. Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.
Callis Duffin K; Merola JF; Christensen R; Latella J; Garg A; Gottlieb AB; Armstrong AW
JAMA Dermatol; 2018 Oct; 154(10):1137-1144. PubMed ID: 29874367
[TBL] [Abstract][Full Text] [Related]
19. Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire, and Hidradenitis Suppurativa Quality of Life Questionnaire.
Ingram JR; Ciaravino V; Rolleri R; Pansar I; Dias-Barbosa C; Kirby JS
Dermatology; 2024; 240(1):65-76. PubMed ID: 37820596
[TBL] [Abstract][Full Text] [Related]
20. Protocol for a Delphi consensus exercise to identify a core set of criteria for selecting health related outcome measures (HROM) to be used in primary health care.
Santaguida P; Dolovich L; Oliver D; Lamarche L; Gilsing A; Griffith LE; Richardson J; Mangin D; Kastner M; Raina P
BMC Fam Pract; 2018 Sep; 19(1):152. PubMed ID: 30185172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
